Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Plasma metabolomic signatures of COPD: A metabolomic severity score for airflow obstruction and emphysema.

ABSTRACT: The NIH sponsored multicenter Genetic Epidemiology of COPD (COPDGene (ClinicalTrials.gov Identifier: NCT01969344) study was approved and reviewed by the institutional review board at all participating centers (1). All study participants provided written informed consent. This study enrolled 10,198 non-Hispanic white (NHW) and African American (AA) individuals from January 2008 until April 2011 (Phase 1) who were aged 45-80 with ≥10 pack-year smoking history and no exacerbations for >30 days. In addition, 465 age and gender matched healthy individuals with no history of smoking were enrolled as controls (mostly at Phase 2). From July 2013 to July 2017, 5,697 subjects returned for an in-person 5-year visit. Each in-person visit included spirometry before and after albuterol, quantitative CT imaging of the chest, and blood sampling. From two clinical centers (National Jewish Health and University of Iowa) 1,136 subjects (1,040 NHW, 96 AA) participated in an ancillary study in which they provided fresh frozen plasma collected using an 8.5 ml p100 tube (Becton Dickinson) at Phase 2. This study is a duplicate of ST001443 (https://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST001443&StudyType=MS&ResultType=5) but differs in analysis and contains batch normalized data using median metabolite values.

ORGANISM(S): Human Homo Sapiens

TISSUE(S): Blood

DISEASE(S): Copd

SUBMITTER: Russell Bowler

PROVIDER: ST002089 | MetabolomicsWorkbench | Tue Feb 08 00:00:00 GMT 2022

REPOSITORIES: MetabolomicsWorkbench

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	mwtab	Other

Items per page:

1 - 1 of 1

Similar Datasets

Plasma metabolomic signatures of COPD

Project description:The NIH sponsored multicenter Genetic Epidemiology of COPD (COPDGene (ClinicalTrials.gov Identifier: NCT01969344) study was approved and reviewed by the institutional review board at all participating centers (1). All study participants provided written informed consent. This study enrolled 10,198 non-Hispanic white (NHW) and African American (AA) individuals from January 2008 until April 2011 (Phase 1) who were aged 45-80 with ≥10 pack-year smoking history and no exacerbations for >30 days. In addition, 465 age and gender matched healthy individuals with no history of smoking were enrolled as controls (mostly at Phase 2). From July 2013 to July 2017, 5,697 subjects returned for an in-person 5-year visit. Each in-person visit included spirometry before and after albuterol, quantitative CT imaging of the chest, and blood sampling. From two clinical centers (National Jewish Health and University of Iowa) 162 subjects at Phase 1 (all NHW) and 1,136 subjects (1,040 NHW, 96 AA) participated in an ancillary study in which they provided fresh frozen plasma collected using an 8.5 ml p100 tube (Becton Dickinson) at Phase 2.

2020-03-19 | ST001443 | MetabolomicsWorkbench

Chronic Obstructive Pulmonary Disease (COPD) Biomarker Identification Study: Serum Lipidomics

Project description:The overall clinical study used a parallel-group, case-controlled study design in order to identify a biomarker or panel of biomarkers for the differentiation of subjects with mild to moderate COPD (GOLD stage I and II), asymptomatic current smokers, former smokers and never-smokers and to compare physiological measurements and quality of life (QoL) across the study groups. The study was conducted between July 2011 and December 2012, at a single clinical site in London, UK, after approval from a UK National Health Service (NHS) ethics committee (The Black County Ethics Committee) and in strict compliance with International Conference on Harmonisation-Good Clinical Practice (ICH-GCP) guidelines. The study has been registered on ClinicalTrials.gov with identifier NCT01780298. Male and female subjects aged between 41 and 70 years were enrolled with a completed total subject number of 60 per group. During the course of the study, sputum, blood, and nasal samples were collected and a number of physiological and clinical measurements were recorded from a total of 240 subjects. Each subject in each of the 3 control groups, namely the healthy smokers, never-smokers and ex-smokers, were matched to subjects in the COPD group by age (+/-5 years), ethnicity, gender, and all smoking subjects had a smoking history of at least 10 pack-years. The study subject were required to attend the study visits after having eaten a light breakfast. Analyses of lipid species were performed in serum samples from a subset of study subjects including 40 never-smokers, 40 former smokers, 40 smokers, and 40 COPD patients by Zora Biosciences Oy (Espoo, Finland). The data from this analysis are reported here.

2017-02-20 | MTBLS358 | MetaboLights

[E-MTAB-612] GENCODE PCR-Seq Batch I

Project description:As part of the ENCODE consortium the GENCODE project is producing a reference gene set through manual and automated gene prediction. Selected transcript models are verified experimentally by RT-PCR amplification followed by sequencing. This is the RNASeq part of batch I, based on annotation from July 2008 (without pseudogenes). ArrayExpress Release Date: 2011-05-01 Publication Title: GENCODE: producing a reference annotation for ENCODE Publication Author List: Harrow J, Denoeud F, Frankish A, Reymond A, Chen CK, Chrast J, Lagarde J, Gilbert JG, Storey R, Swarbreck D, Rossier C, Ucla C, Hubbard T, Antonarakis SE, Guigo R Person Roles: submitter Person Last Name: Kokocinski Person First Name: Felix Person Mid Initials: Person Email: fsk@sanger.ac.uk Person Phone: -498006 Person Address: Wellcome Trust Genome Campus, Hinxton, UK Person Affiliation: Wellcome Trust Sanger Institute Person Roles: investigator Person Last Name: Hubbard Person First Name: Tim Person Mid Initials: Person Email: th@sanger.ac.uk Person Phone: -498055 Person Address: Wellcome Trust Genome Campus, Hinxton, UK Person Affiliation: Wellcome Trust Sanger Institute Person Roles: investigator Person Last Name: Reymond Person First Name: Alexandre Person Mid Initials: Person Email: Alexandre.Reymond@unil.ch Person Phone: Person Address: Lausanne, Switzerland Person Affiliation: University of Lausanne For data usage terms and conditions, please refer to http://www.genome.gov/27528022 and http://www.genome.gov/Pages/Research/ENCODE/ENCODEDataReleasePolicyFinal2008.pdf

2011-07-14 | GSE30619 | GEO

Proteomics of JHS samples identifies proteins associated with heart failure

Project description:RELEVANCE: Identifying early plasma protein biomarkers that predict the development of heart failure (HF) following myocardial infarction (MI) will help to stratify at risk subjects and provide insight into more effective therapeutic strategies. OBJECTIVE/HYPOTHESIS: The goal of this study was to determine markers of HF in African Americans, using plasma samples collected before the development of symptoms. We propose that early plasma glycoprotein changes will link to later development of heart failure. ApolipoproteinF will be the strongest indicator. METHODS: Plasma samples from a subset of Jackson Heart Study participants with a history of MI but without prevalent heart failure (HF) at visit 2 (2005-2008) were analyzed by glycoproteomics. Individuals were grouped into those who experienced subsequent HF hospitalization after visit 2 (n=15; 3 men/ 12 women) and those without HF hospitalization through 2012 (n=45; 24 men/ 21 women). N-linked plasma glycopeptides were quantified by solid-phase extraction coupled to mass spectrometry and identified using RefSeq and SwissProt. Proteins were mapped for biological processes and functional pathways using Ingenuity Pathway Analysis (IPA) and linked to clinical characteristics.

2018-08-30 | PXD009870 | Pride

[E-MTAB-387] RNA sequencing in E. coli K12

Project description:Transcriptome sequencing of E.coli K12 in LB media in early exponential phase and transition to stationary phase ArrayExpress Release Date: 2010-09-30 Person Roles: submitter Person Last Name: Martincorena Person First Name: Inigo Person Mid Initials: Person Email: martinco@ebi.ac.uk Person Phone: Person Address: Person Affiliation: EBI

2011-02-05 | GSE24998 | GEO

[E-MTAB-587] PCR_artifacts

Project description:WARNING: This library was yield low amount of material and it was over-amplified by PCR. This libraries are used study the robustness of several statitical methods against PCR artifacts. ChIP experiments were performed on Arabidopsis wildtype inflorescences using an antibody raised against a C-terminal peptide of SEP3. ArrayExpress Release Date: 2011-04-27 Publication Title: ChIP-seq Analysis in R (CSAR): An R package for the statistical detection of protein-bound genomic regions Publication Author List: Jose M. Muino, Kerstin Kaufmann, Roeland C. H. J. van Ham, Gerco C. Angenent, and Pawel Krajewski Person Roles: submitter Person Last Name: Muino Person First Name: Jose Person Mid Initials: M. Person Email: jose.muino@wur.nl Person Phone: 0317-481122 Person Address: Droevendaalsesteeg 1, P.O. Box 16, 6700 AA Wageningen, The Netherlands Person Affiliation: Plant Research International B.V.

2011-07-14 | GSE30616 | GEO

AGATA: First nationwide molecular screening program in Spain for patients with advanced breast cancer

Project description:The SOLTI-1301 AGATA study aimed to assess the feasibility of a multi-institutional molecular screening program to better characterize the genomic landscape of advanced breast cancer (ABC) and to facilitate patient access to matched-targeted therapies in Spain. Between September 2014 and July 2017, 305 patients with ABC from 10 institutions were enrolled.

2021-11-01 | GSE182852 | GEO

Proteomics of Exhaled Breath Condensate in COPD patients

Project description:Exhaled breath condensate(EBC) is now a safe and clinically significant measurement which has a huge potential to measure biomarkers in COPD. Previous studies profiled the pooled EBC samples from COPD or control participants due to technological limitations. In our study, 32 COPD patients and 28 control individuals were enrolled, and their EBC were collected. After matching with sex, age and smoking history, EBC samples of 19 COPD patients and 19 control individuals were analyzed using tandem mass tags (TMTs) quantitative mass spectrometry individually.

2019-08-15 | PXD013068 |

RNA sequencing of sputum cells from a phase IIa placebo controlled clinical trial of Risankizumb in severe asthma

Project description:Interleukin (IL)-23 is implicated in T2 and T17-mediated airway inflammation, supporting a role in asthma. We undertook a Phase II, randomized, double-blind, placebo-controlled, 24-week, parallel-group, multicenter trial to assess the efficacy and safety of risankizumab, an IL23p19 monoclonal antibody, administered subcutaneously (90 mg 4 weekly) in adults with severe asthma. Sputum samples were collected at several timepoints: visit 1B (week -3), visit 2 (week 0 proir to treatment), visit 7 (week 20), visit 8 (week 24, end of treatment), visit 12 (week 40, end of observation). RNA sequencing of sputum cells.

2024-02-10 | GSE167074 | GEO

Genome-wide screening of transcriptional modulation in non-smoking female lung cancer in Taiwan

Project description:Although smoking is the major risk factor for lung cancer, only 7% of female lung cancer patients in Taiwan have a history of cigarette smoking, extremely lower than those in Caucasian females. This report is a comprehensive analysis of the molecular signature of non-smoking female lung cancer in Taiwan.

2011-01-30 | GSE19804 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data